公开(公告)号：US20170197960A1

公开(公告)日：2017-07-13

申请号：US15316534

申请日：2015-06-05

Applicant: BIOGEN MA INC.

Inventor： Gnanasambandam Kumaravel ,  Hairuo Peng ,  Zhili Xin

IPC: C07D471/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  C07D487/04 ,  C07D519/00

Abstract: Compounds of formula (I) can modulate the activity of autotaxin (ATX).

公开(公告)号：US20170088835A1

公开(公告)日：2017-03-30

申请号：US15267408

申请日：2016-09-16

Applicant: Biogen MA Inc. ,  Cold Spring Harbor Laboratory

Inventor： Brenda F. Baker ,  Adrian R. Krainer ,  Yimin Hua

IPC: C12N15/113

CPC classification number: C12N15/113 ,  C12N15/111 ,  C12N2310/11 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2320/33 ,  C12N2310/3525

Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a cell, tissue or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.

公开(公告)号：USD781330S1

公开(公告)日：2017-03-14

申请号：US29541770

申请日：2015-10-07

Applicant: BIOGEN MA INC.

Designer： Jane Relton Rhodes ,  Wendy Gabel ,  Erik Mednis

公开(公告)号：US20170049904A1

公开(公告)日：2017-02-23

申请号：US15237064

申请日：2016-08-15

Applicant: BIOGEN MA INC.

Inventor： KoChung LIN ,  Blake PEPINSKY ,  Ling Ling CHEN ,  Donna M. HESS ,  Edward Y. LIN ,  Russell C. PETTER ,  Darren P. BAKER

IPC: A61K47/48 ,  A61K38/21 ,  A61K9/00 ,  A61K45/06

CPC classification number: A61K47/48215 ,  A61K9/0019 ,  A61K38/215 ,  A61K45/06 ,  A61K47/60 ,  C07K14/565

Abstract: The invention relates to novel polyalkylene glycol compounds and methods of using them. In particular, compounds comprising a novel polyethylene glycol conjugate are used alone, or in combination with antiviral agents to treat a viral infection, such as chronic hepatitis C.

Abstract translation: 本发明涉及新型聚亚烷基二醇化合物及其使用方法。 特别地，包含新型聚乙二醇缀合物的化合物单独使用或与抗病毒剂组合用于治疗病毒感染，例如慢性丙型肝炎。

公开(公告)号：US20170027956A1

公开(公告)日：2017-02-02

申请号：US15055910

申请日：2016-02-29

Applicant: Biogen MA Inc. ,  Sunesis Pharmaceuticals, Inc.

Inventor： Brian T. Hopkins ,  Daniel Scott ,  Patrick Conlon ,  Tracy J. Jenkins ,  Noel Powell ,  Bing Guan ,  Julio H. Cuervo ,  Deping Wang ,  Art Taveras

IPC: A61K31/553 ,  A61K31/4545 ,  A61K31/55 ,  A61K31/519 ,  A61K31/506 ,  A61K31/52 ,  A61K31/496 ,  A61K31/5377

CPC classification number: A61K31/553 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/519 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/55 ,  C07D401/12 ,  C07D403/04 ,  C07D413/12 ,  C07D471/04 ,  C07D473/34 ,  C07D487/04 ,  C07D513/04 ,  C07D519/00

Abstract: The present invention provides compounds useful as inhibitors of Tec family kinases, compositions thereof, and methods of using the same.

Abstract translation: 本发明提供可用作Tec家族激酶抑制剂的化合物，其组合物及其使用方法。

公开(公告)号：US20160347787A1

公开(公告)日：2016-12-01

申请号：US15116456

申请日：2015-02-04

Applicant: BIOGEN MA INC.

Inventor： Austen NG ,  Robert S. GRONKE

IPC: C07K1/18 ,  C07K14/755 ,  C07K14/715

CPC classification number: C07K1/18 ,  C07K14/7151 ,  C07K14/755 ,  C07K2319/30

Abstract: The present invention relates to improved methods in the separation recombinant polypeptides with post-translational modifications from complex mixtures through the use of a cation exchange medium.

Abstract translation: 本发明涉及通过使用阳离子交换介质从复杂混合物中分离具有翻译后修饰的重组多肽的改进方法。

公开(公告)号：US09506867B2

公开(公告)日：2016-11-29

申请号：US14103801

申请日：2013-12-11

Applicant: Biogen MA Inc.

Inventor： Justin Moretto ,  Kelly Wiltberger

IPC: G01J3/44 ,  G01N21/65

CPC classification number: G01N21/65 ,  G01J3/44

Abstract: In some embodiments, aspects of the disclosure relate to methods of evaluating cell culture materials, for example, nutrient materials, or other materials that can be used in cell culture media.

Abstract translation: 在一些实施方案中，本公开的方面涉及评估细胞培养物质，例如营养物质或可用于细胞培养基的其它材料的方法。

公开(公告)号：US09499485B2

公开(公告)日：2016-11-22

申请号：US14420025

申请日：2013-08-05

Applicant: BIOGEN MA INC.

Inventor： Kevin Guckian ,  Gnanasambandam Kumaravel ,  Bin Ma ,  Lihong Sun ,  Zhili Xin ,  Lei Zhang

IPC: C07D451/02 ,  C07D211/62 ,  A61K31/122 ,  A61K45/06 ,  A61K31/192 ,  A61K31/216 ,  A61K31/439 ,  A61K31/445 ,  A61K31/45 ,  C07C229/14 ,  C07C229/48 ,  C07D211/60 ,  A61K31/196 ,  A61K31/197 ,  A61K31/198 ,  A61K31/46 ,  C07D211/34 ,  C07D451/14

CPC classification number: C07D211/62 ,  A61K31/122 ,  A61K31/192 ,  A61K31/196 ,  A61K31/197 ,  A61K31/198 ,  A61K31/216 ,  A61K31/439 ,  A61K31/445 ,  A61K31/45 ,  A61K31/46 ,  A61K45/06 ,  C07C229/14 ,  C07C229/48 ,  C07C2601/14 ,  C07D211/34 ,  C07D211/60 ,  C07D451/02 ,  C07D451/14 ,  A61K2300/00

Abstract: Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).

Abstract translation: 式（I）化合物可以调节一种或多种SIP受体的活性和/或自分泌素（ATX）的活性。

公开(公告)号：US20160310419A1

公开(公告)日：2016-10-27

申请号：US15102306

申请日：2014-12-12

Applicant: BIOGEN MA INC.

Inventor： Peter Zawaneh ,  Shyam B. Karki ,  Michael Kaufman ,  Cheuk-Yui Leung ,  Jinquan Dong ,  Ernest Quan ,  Kalyan Vasudevan

IPC: A61K9/00 ,  A61K9/14 ,  A61K9/20 ,  A61K9/50 ,  A61K9/48 ,  A61K31/22 ,  A61K9/28

CPC classification number: A61K9/0065 ,  A61K9/0004 ,  A61K9/14 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2086 ,  A61K9/2846 ,  A61K9/2853 ,  A61K9/2866 ,  A61K9/2886 ,  A61K9/4808 ,  A61K9/5026 ,  A61K9/5031 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5073 ,  A61K31/22

Abstract: A controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof is delivered to the subject. Also provided is a method of treating a disease or disorder (e.g., multiple sclerosis) by orally administering a controlled release dosage form containing monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomethyl fumarate, a compound that can be metabolized into monomethyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof.

Abstract translation: 含有富马酸单甲酯，可以在体内代谢为富马酸单甲酯的化合物或其药学上可接受的盐或其组合的控释剂型，其中富马酸单甲酯，可在体内代谢成富马酸甲酯的化合物或 其药学上可接受的盐或其组合被递送至受试者。 还提供了通过口服施用含有富马酸单甲酯，可以在体内代谢成富马酸甲酯的化合物或其药学上可接受的盐或其组合来治疗疾病或病症（例如多发性硬化症）的方法 其中富马酸单甲酯，可在体内代谢成富马酸单甲酯的化合物或其药学上可接受的盐或其组合。

公开(公告)号：US20160304928A1

公开(公告)日：2016-10-20

申请号：US15000522

申请日：2016-01-19

Applicant: Biogen MA Inc.

Inventor： William YANG ,  Yao-Ming Huang ,  Kyle McElearney ,  Lia Tescione ,  James Lambropoulos ,  An Zhang ,  Valerie Tsang ,  Thomas Ryll

IPC: C12P21/00 ,  C12N5/00

CPC classification number: C12P21/005 ,  C12N5/0018 ,  C12N2500/20 ,  C12N2500/30 ,  C12N2500/34 ,  C12N2500/40 ,  C12N2500/90 ,  C12N2501/04 ,  C12N2511/00

Abstract: The present invention pertains to a cell culture medium comprising media supplements that are shown to control recombinant protein glycosylation and/or cell culture in a controlled or modulated (shifted) temperature to control recombinant protein glycosylation and/or cell culture with controlled or modulated seed density to control recombinant protein glycosylation, and methods of using thereof. The present invention further pertains to a method of controlling or manipulating glycosylation of a recombinant protein of interest in a large scale cell culture.